ArticleBMC cancer2025
Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes.Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to compare the demographic characteristics, clinicopathological factors, and survival outcomes between Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) using the Fudan University Shanghai Cancer Center (FUSCC) database.
methodsOver 12,000 patients were treated at FUSCC from January 2000 to December 2019. We identified 403 patients diagnosed with ILC and 11,829 with IDC. The chi-square test was employed to compare clinical demographics, tumor characteristics, and treatments, while Kaplan-Meier survival analysis was used to obtain Disease-Free Survival (DFS) and Overall Survival (OS) curves. Cox proportional hazard regression models established hazard ratios (HR), reported with a 95% confidence interval (CI).
resultsILC exhibited distinctive characteristics compared to IDC, including older age, larger tumor size, higher estrogen receptor and progesterone receptor expression, and significantly lower HER-2 expression. The disease-free survival (DFS: ILC 86.6% vs. IDC 90.2%, P = 0.007) and overall survival (OS: ILC 90.5% vs. IDC 92.4%, P = 0.038) were worse for ILC than IDC. After applying Propensity Score Matching (PSM), the overall survival (OS: ILC 90.5% vs. IDC 93.2%, P = 0.046) was worse for ILC compared to IDC.
conclusionPatients diagnosed with Invasive Lobular Carcinoma (ILC) encounter distinct challenges, characterized by a lower survival rate, an elevated risk of metastasis when compared to those with Invasive Ductal Carcinoma (IDC). In order to gain a comprehensive understanding of ILC and to develop tailored, effective treatment strategies, it is imperative to investigate a variety of influencing factors in future research endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.